Frontiers In Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies
In-Person Event
Apr 20 - 21, 2018
Chicago, Illinois, USA
OVERVIEW
Frontiers In Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies is organized by The University of Chicago - Center for Continuing Medical Education and will be held during Apr 20 - 21, 2018 at The Gwen, a Luxury Collection Hotel, Michigan Avenue Chicago, Chicago, Illinois, United States of America.
The target audience for this medical event for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other healthcare professionals currently involved in providing cancer genetics risk assessment services or initiating such services in their healthcare system. Special efforts will be made to educate clinicians practicing in geographically or socioeconomically underserved communities. This CME Conference has been approved for a maximum of 15.00 AMA PRA Category 1 Credit.
Course Description:
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.
Learning Objectives:
At the conclusion of this activity, participants will be able to:
• Identify how advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
• Recognize advances in the clinical management of patients with inherited cancer syndromes including breast, prostate, gastrointestinal, and hematologic malignancies;
• Discuss integration of novel cancer therapies based on genomic alterations in tumor tissue that may reveal germline mutations such as MLH1 and BRCA mutations into the practice of oncology;
• Describe how to manage cancer patients from high risk families using a globally-informed perspective;
• Discuss emerging models for cancer risk assessment and genetic testing including integration of a polygenic risk score;
• Recognize the ethical, legal, and social implications of genomic testing in healthy populations.
Additional details will be posted as soon as they are available.
The target audience for this medical event for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other healthcare professionals currently involved in providing cancer genetics risk assessment services or initiating such services in their healthcare system. Special efforts will be made to educate clinicians practicing in geographically or socioeconomically underserved communities. This CME Conference has been approved for a maximum of 15.00 AMA PRA Category 1 Credit.
Course Description:
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.
Learning Objectives:
At the conclusion of this activity, participants will be able to:
• Identify how advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
• Recognize advances in the clinical management of patients with inherited cancer syndromes including breast, prostate, gastrointestinal, and hematologic malignancies;
• Discuss integration of novel cancer therapies based on genomic alterations in tumor tissue that may reveal germline mutations such as MLH1 and BRCA mutations into the practice of oncology;
• Describe how to manage cancer patients from high risk families using a globally-informed perspective;
• Discuss emerging models for cancer risk assessment and genetic testing including integration of a polygenic risk score;
• Recognize the ethical, legal, and social implications of genomic testing in healthy populations.
Additional details will be posted as soon as they are available.
KEY DATES
20 Apr, 2018
Event Start Date
21 Apr, 2018
Event End Date
SPECIALITIES
OncologySUGGESTED HOTELS
CONFERENCE VENUE
The Gwen, a Luxury Collection Hotel, Michigan Avenue ChicagoRELATED CONFERENCES & LIVE WEBINARS
Quick Links